BiomX (NYSEAMERICAN:PHGE) Issues Earnings Results

BiomX (NYSEAMERICAN:PHGE) announced its earnings results on Wednesday. The company reported ($0.37) earnings per share for the quarter, FiscalAI reports.

BiomX Price Performance

PHGE opened at $0.14 on Friday. The stock has a market capitalization of $1.65 million, a PE ratio of -0.04 and a beta of 1.35. BiomX has a 12-month low of $0.12 and a 12-month high of $12.29. The firm’s fifty day moving average price is $0.27 and its 200 day moving average price is $2.16.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to its most recent filing with the SEC. The fund purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX at the end of the most recent quarter. 40.57% of the stock is owned by institutional investors and hedge funds.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.